Holden to Leave Illumina; Yousaf Tapped to Head ABI’s MCB Systems Group; NIGMS Appoints Lee as Executive Officer, and Others | GenomeWeb
NEW YORK (GenomeWeb News) - Arthur Holden plans to leave his post as vice president of corporate and market development at Illumina in mid-October, the company said this week in a filing with the US Securities and Exchange Commission.
Holden is director of the Serious Adverse Events Consortium, a pharma-backed initiative announced this week that aims to find genetic causes for severe adverse events that hamper drug development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.